BCR-ABL激酶区突变在酪氨酸激酶抑制剂耐药慢性髓性白血病患者中的分布及其影响因素

OBJECTIVE: To explore BCR-ABL kinase domain mutation profiles and clinical variables associated with them in tyrosine kinase inhibitor (TKI)-resistant patients with chronic myeloid leukemia (CML). METHODS: Imatinib-, nilotinib-, and/or dasatinib-resistant patients with CML who screened BCR-ABL mutat...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2020
Materias:
论著
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378281/
https://www.ncbi.nlm.nih.gov/pubmed/32654459
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.06.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378281/
https://www.ncbi.nlm.nih.gov/pubmed/32654459
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.06.006

Ejemplares similares